Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD Consortium.

ABSTRACT: Most patients with epithelial ovarian cancer (EOC) are diagnosed at advanced stage and have a poor prognosis. However, a small proportion of these patients will survive, whereas others will die very quickly. Clinicopathological factors do not allow precise identification of these subgroups. Thus, we have validated a molecular subclassification as new prognostic factor in EOC. One hundred and ninety-four patients with Stage II-IV EOC were characterized by whole-genome expression profiling of tumor tissues and were classified using a published 112 gene set, derived from an International Federation of Gynecology and Obstetrics (FIGO) stage-directed supervised classification approach. The 194 tumor samples were classified into two subclasses comprising 95 (Subclass 1) and 99 (Subclass 2) tumor

SUBMITTER: Pils D 

PROVIDER: S-EPMC7659264 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature